ES8505666A1 - Procedimiento para preparar derivados de piperazina. - Google Patents

Procedimiento para preparar derivados de piperazina.

Info

Publication number
ES8505666A1
ES8505666A1 ES522037A ES522037A ES8505666A1 ES 8505666 A1 ES8505666 A1 ES 8505666A1 ES 522037 A ES522037 A ES 522037A ES 522037 A ES522037 A ES 522037A ES 8505666 A1 ES8505666 A1 ES 8505666A1
Authority
ES
Spain
Prior art keywords
antiatherosclerotic
piperazine derivatives
pyrazinyl
piperazinethiocarboxanilide
piperazinethiocarboxamides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES522037A
Other languages
English (en)
Other versions
ES522037A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/375,507 external-priority patent/US4439606A/en
Priority claimed from US06/375,526 external-priority patent/US4450272A/en
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of ES8505666A1 publication Critical patent/ES8505666A1/es
Publication of ES522037A0 publication Critical patent/ES522037A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
    • C07D241/38—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with only hydrogen or carbon atoms directly attached to the ring nitrogen atoms
    • C07D241/40—Benzopyrazines
    • C07D241/44—Benzopyrazines with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

PROCEDIMIENTO PARA PREPARAR DERIVADOS DE PIPERAZINA.CONSISTE EN HACER REACCIONAR A UN COMPUESTO DE FORMULA (II) CON UN COMPUESTO DE FORMULA (III), EN UN DISOLVENTE ORGANICO INERTE, A LA TEMPERATURA DE EBULLICION DEL DISOLVENTE Y DURANTE 24 HORAS, PARA OBTENER UN COMPUESTO DE FORMULA (I). SIENDO: A, FENILO, 2-PIRAZINILO, 20QUINOLNILO Y OTRAS; B, FENILO, FENILO MONO O POLISUSTITUIDO CON SUSTITUYENTES COMO F, ALQUILO DE C 1 A 4 Y OTROS Y R, H, ALQUILO DE C 1 A 3.SE UTILIZAN PARA ALIVIARLA ARTEROESCLEROSIS EN MAMIFEROS.
ES522037A 1982-05-06 1983-05-03 Procedimiento para preparar derivados de piperazina. Granted ES522037A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/375,507 US4439606A (en) 1982-05-06 1982-05-06 Antiatherosclerotic 1-piperazinecarbonyl compounds
US06/375,526 US4450272A (en) 1982-05-06 1982-05-06 Antiatherosclerotic 1-piperazine-thicarboxamides

Publications (2)

Publication Number Publication Date
ES8505666A1 true ES8505666A1 (es) 1985-06-01
ES522037A0 ES522037A0 (es) 1985-06-01

Family

ID=27007085

Family Applications (2)

Application Number Title Priority Date Filing Date
ES522037A Granted ES522037A0 (es) 1982-05-06 1983-05-03 Procedimiento para preparar derivados de piperazina.
ES535527A Granted ES535527A0 (es) 1982-05-06 1984-08-30 Procedimiento para preparar derivados de piperazina

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES535527A Granted ES535527A0 (es) 1982-05-06 1984-08-30 Procedimiento para preparar derivados de piperazina

Country Status (12)

Country Link
EP (1) EP0094498A3 (es)
KR (1) KR840004733A (es)
AU (1) AU1425183A (es)
DD (1) DD215543A5 (es)
DK (1) DK202183A (es)
ES (2) ES522037A0 (es)
FI (1) FI831550A (es)
GR (1) GR78261B (es)
IL (1) IL68304A0 (es)
NZ (1) NZ204054A (es)
PL (1) PL241807A1 (es)
PT (1) PT76647A (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05507702A (ja) * 1990-05-30 1993-11-04 アメリカン・ホーム・プロダクツ・コーポレイション 置換アリールスルホンアミド類およびベンズアミド類
JPH05255089A (ja) * 1991-12-18 1993-10-05 Sanwa Kagaku Kenkyusho Co Ltd 抗ウイルス剤
WO2005121094A1 (en) * 2004-06-09 2005-12-22 Pfizer Limited Piperazine and piperidine derivatives as anti-hiv-agents
WO2008013622A2 (en) * 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
CN104379563B (zh) 2012-04-10 2018-12-21 加利福尼亚大学董事会 用于治疗癌症的组合物和方法
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
BR112017021869A2 (pt) 2015-04-10 2018-12-11 Araxes Pharma Llc compostos quinazolina substituídos e métodos de uso dos mesmos
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
EP3356339A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
WO2017058728A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
WO2017058915A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356354A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
EP3356347A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
CN108779097A (zh) 2015-11-16 2018-11-09 亚瑞克西斯制药公司 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
WO2017172979A1 (en) 2016-03-30 2017-10-05 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3523289A1 (en) 2016-10-07 2019-08-14 Araxes Pharma LLC Heterocyclic compounds as inhibitors of ras and methods of use thereof
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110382482A (zh) 2017-01-26 2019-10-25 亚瑞克西斯制药公司 稠合的杂-杂二环化合物及其使用方法
WO2018140599A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CN110869357A (zh) 2017-05-25 2020-03-06 亚瑞克西斯制药公司 化合物及其用于治疗癌症的使用方法
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2602792A (en) * 1950-11-24 1952-07-08 American Cyanamid Co 1-carbocycliccarbamyl-4-heterocyclic-piperazines
US2666055A (en) * 1952-10-27 1954-01-12 American Cyanamid Co 1-thiocarbamyl-4-heterocyclic piperazines
DE1077218B (de) * 1955-05-11 1960-03-10 American Cyanamid Co Verfahren zur Herstellung von gegen Hakenwurminfektionen wirksamen N, N-disubstituierten Piperazinen
CH583232A5 (es) * 1973-02-02 1976-12-31 Wander Ag Dr A
FI193974A (es) * 1973-07-13 1975-01-14 Merck & Co Inc
EG12387A (en) * 1975-04-21 1978-12-31 Merck & Co Inc Process for preparing of piperazinyl pyrazines

Also Published As

Publication number Publication date
PL241807A1 (en) 1986-02-11
FI831550A (fi) 1983-11-07
NZ204054A (en) 1987-04-30
PT76647A (en) 1983-06-01
FI831550A0 (fi) 1983-05-05
ES8506682A1 (es) 1985-07-16
AU1425183A (en) 1983-11-10
DD215543A5 (de) 1984-11-14
DK202183A (da) 1983-11-07
EP0094498A3 (en) 1985-04-03
IL68304A0 (en) 1983-07-31
EP0094498A2 (en) 1983-11-23
DK202183D0 (da) 1983-05-05
KR840004733A (ko) 1984-10-24
ES522037A0 (es) 1985-06-01
ES535527A0 (es) 1985-07-16
GR78261B (es) 1984-09-26

Similar Documents

Publication Publication Date Title
ES8506682A1 (es) Procedimiento para preparar derivados de piperazina
PL240871A1 (en) Process for preparing novel derivatives of 1,2,4-triazine and pyrazine
BG46159A3 (en) Method for preparing of prteine, heterolog microorganism
IL63839A (en) N-hetero-aryl-benzamides and benzcarbothioamides,process for their preparation,herbicidal compositions containing them and method of using them
AU581772B2 (en) Method for highly efficient laundering of textiles
ES8300758A1 (es) Un procedimiento para la preparacion de nuevos pirazimil-1,2,4 oxadiazol-5-onas.
ZA853571B (en) Compositions and process for treating textiles
ES8308224A1 (es) Una suspension de agua carbonosa.
GB2033906B (en) Water-soluble compounds derived from extracts of streptomyces stimulosus process for their production and compositions containing them
PL245404A1 (en) Process for preparing novel derivatives of 1,4:3,6-dianhydrohexites
EP0226250A3 (en) Process for the preparation of a polysaccharide in oil dispersion and dispersion obtained thereof
ES8507001A1 (es) Un metodo de proteccion de una bacteria contra un bacteriofago natural.
PL243409A1 (en) Process for preparing novel derivatives of 1,2,4-triazole
FR2510997B1 (es)
MY107160A (en) N-aryl-3-aryl-4-substituted-4,5-dihydro-1h-pyrazole-1- carboxamides and processes for their production.
HUT36076A (en) Improved process for production of 1,8-dihidroxi-10-acil-9-antrons
ES450095A1 (es) Procedimiento para la preparacion de 2-cloro-n-isopropil-2',3'-dimetilicetanilida.
AU1374183A (en) New cyanoguanidines, method for obtaining them and pharmac- eutical compositions containing them
YU43601B (en) Process for preparation of 2-(2-fluoro-4-trifluoro-methyl-phenyl) 1,3 di(1,2,4-triazole-1-ile)-2-propanol
EP0093485A3 (en) Process for the preparation of substituted 3-oxa-1-aza-bicyclo(4.2.0)octan-8-ones, and intermediates obtained thereby
DE3165793D1 (en) Solvated salts of 2,4-dinitrophenyl cyanamides, process for preparing them and their application
PL236659A1 (en) Process for preparing 3,5-substituted derivatives of 2-thiohydantoin
SU1072420A1 (ru) Бис-[(3,5-ди-трет-бутил-4-оксифенил)-алкил]-сульфиды в качестве термостабилизаторов полиэтилена
ES8607929A1 (es) Un procedimiento para preparar un 10-ftalil-1, 5-diprotegido-1, 5, 10-triazadecano
ES8700226A1 (es) Un procedimiento para la preparacion en forma cristalina de una mezcla de sales diastereomericas del ester 1-pivaloiloxietilico de (s)-3-(3,4-dihidroxifenil)-2-metilalanina